Novartis Drops SCD Gene Therapy Program with Intellia

Novartis has abandoned its ex vivo sickle cell disease (SCD) program developed using Intellia Therapeutics’ CRISPR gene editing platform, according to Intellia's 2022 financial results released Thursday.